rat igg2a be0089 2a3 antibody  (Bio X Cell)

Journal: Frontiers in Immunology

Article Title: Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy

doi: 10.3389/fimmu.2022.937924

Figure Lengend Snippet: Effective low-dose Anlotinib improved anti-PD-1 therapy in both short- and long-term treatment regimens. EO771 tumor-bearing mice were prepared, and Anlotinib treatments (2 or 8 mg/kg/daily) were conducted as described in Figure 1 . Treatments with anti-PD-1 or isotype IgG (5 mg/kg) were initiated when tumors reached 3–4 mm in diameter and continued every 3 days. Tumor growth curves and tumor weights with short-term (A) or long-term (B) combinations of Anlotinib and anti-PD-1 therapy are shown. The significance was determined by one-way ANOVA ( n = 7–15 mice per group). The data are presented as means ± SEM. NS, no significant difference; ** p < 0.01; *** p < 0.001.

Article Snippet: Anti-mouse PD-1 antibody (Lot number 190312007) was provided by Innovent Biologics Co. Ltd. (Suzhou, China), and anti-CD8a monoclonal antibody (Clone 53-6.72), anti-CD4 monoclonal antibody (Clone GK1.5), or their isotype-matched control antibody IgG2a (2A3) were purchased from Bio X Cell (New Hampshire, USA).

Techniques:

Journal: Frontiers in Immunology

Article Title: Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy

doi: 10.3389/fimmu.2022.937924

Figure Lengend Snippet: In vivo depletion of CD8 + T cells partially reversed the antitumor effects of the combination therapy, while Anlotinib treatments inhibited tumor growth independent of IFN-γ. WT or IFN-γ −/− mice were orthotopically inoculated with 2 × 10 5 EO771 breast tumor cells. When EO771 breast tumors reached 3–4 mm in diameter, mice were randomly divided into appropriate groups and treated with ddH 2 O or Anlotinib (2 mg/kg/daily), IgG, or anti-PD-1 antibodies (5 mg/kg every 3 days). Some groups of mice were also treated with isotype 2A3, anti-CD8, or/and anti-CD4 antibodies (200 µg/mouse) on days 5, 7, and 12 after tumor cell inoculation. (A) The impacts of IFN-γ on tumor growth upon Anlotinib treatments. (B) The influences of T-cell depletion on tumor growth upon Anlotinib and anti-PD-1 combination therapy. The significance was determined by one-way ANOVA ( n = 7 mice per group in A, and n = 10–12 mice per group in B ). The data are presented as means ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Anti-mouse PD-1 antibody (Lot number 190312007) was provided by Innovent Biologics Co. Ltd. (Suzhou, China), and anti-CD8a monoclonal antibody (Clone 53-6.72), anti-CD4 monoclonal antibody (Clone GK1.5), or their isotype-matched control antibody IgG2a (2A3) were purchased from Bio X Cell (New Hampshire, USA).

Techniques: In Vivo